Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Imfinzi (durvalumab) Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
The Imfinzi (durvalumab) market has experienced swift expansion within the past few years and is set to rise from $3.01 million in 2025 to $3.36 million in 2026, reflecting a compound annual growth rate (CAGR) of 11.4%. This historical growth was driven by factors including the clinical effectiveness of immune checkpoint inhibitors, an increase in lung cancer incidence, oncology-focused regulatory approvals, enhanced survival rates, and robust investment from pharmaceutical companies.
The anticipated expansion of the durvalumab (Imfinzi) market is projected to be swift over the coming years. By 2030, its value is forecast to reach $5.11 million, driven by an 11.1% compound annual growth rate (CAGR). This projected growth during the forecast period stems from several factors: the drug’s entry into new cancer indications, a rise in immunotherapy availability, an uptick in oncology clinical trials, higher healthcare spending on cancer treatments, and the creation of combination therapy protocols. Key developments shaping this period include the growing preference for PD-L1 inhibitors, the broader application of immunotherapy in lung cancer cases, an increase in combined immuno-oncology treatment plans, a heightened emphasis on biomarker-guided therapies, and the drug’s more extensive implementation across a range of solid tumors.
Download A Free Sample Report For Comprehensive Market Insights:
Imfinzi (durvalumab) Market Demand Drivers: What Is Fueling Industry Growth?
The anticipated increase in cancer cases is expected to fuel expansion in the Imfinzi (durvalumab) market moving forward. Cancer describes a set of illnesses involving abnormal cells that multiply and spread uncontrollably within the body, potentially infiltrating and damaging healthy tissue. This rising trend in cancer incidence is largely propelled by an aging demographic, since cancer risk elevates with advancing age, along with lifestyle influences like tobacco use, inadequate nutrition, and excess weight, which all contribute to increased cancer rates. Durvalumab, marketed as Imfinzi, functions in cancer treatment by blocking the PD-L1 protein, thereby hindering cancer cells from escaping immune system recognition. As an illustration, data from the National Cancer Institute (NIH), a U.S. government entity, indicated in May 2024 that there were 18.1 million cancer survivors in the United States in 2022, with projections showing an increase to 22.5 million by 2032. Consequently, the escalating frequency of cancer is propelling growth within the Imfinzi (durvalumab) market.
The expansion of personalized medicine is anticipated to drive growth in the Imfinzi (durvalumab) market looking ahead. Personalized medicine represents a healthcare approach that customizes treatment and medical strategies based on each patient’s unique attributes, including genetic factors, lifestyle, and environment, with the goal of delivering the most effective and accurate results. The increasing adoption of personalized medicine stems from developments in genomic technologies, a deeper comprehension of molecular biology, wider accessibility to precise diagnostic instruments, and a push for targeted therapies that boost patient outcomes while reducing adverse effects. Imfinzi (durvalumab) supports personalized medicine through its action of targeting and blocking the PD-L1 protein, allowing customized immunotherapy approaches for cancer patients that are adapted to specific tumor biology and immune system profiles, thereby improving treatment success and limiting unnecessary side effects. For example, as reported by the Personalized Medicine Coalition, a representative U.S. organization, in 2023, the FDA approved personalized treatments for 34% of new drugs in 2022, and over the prior eight years, these therapies received approval for at least 25% of new medications. Hence, the increasing adoption of personalized medicine is driving the Imfinzi (durvalumab) market forward.
Imfinzi (durvalumab) Market Segment Performance And Strategic Opportunities
The imfinzi (durvalumab) market covered in this report is segmented –
1) By Type: 2.4mL Injection, 10mL Injection
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications
Imfinzi (durvalumab) Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the Global Imfinzi (durvalumab) market are concentrating on extending its approved uses, especially perioperative application alongside chemotherapy, to secure a market edge. As an example, in January 2023, AstraZeneca plc, a biopharmaceutical firm headquartered in the UK, revealed that IMFINZI combined with chemotherapy achieved more than double the pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This approach includes a two-phase treatment before and after surgery, along with sustained immune activation advantages. Such expansion into gastrointestinal cancer indications highlights AstraZeneca’s effort to strengthen its clinical presence and foster sustained demand growth. Nevertheless, this approach carries regulatory challenges, given that the more intricate treatment protocols demand supplementary trial evidence and health economic verification.
Imfinzi (durvalumab) Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.
Access The Complete Imfinzi (durvalumab) Market Report:
Imfinzi (durvalumab) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model